Health care costs are a significant area of concern for everyone from patients to policymakers. Health services research evidence looks at different ways to address cost growth, encourage efficiency and quality, and provide for care via insurance, Medicare and Medicaid so that people receive the best care at the best value.
Despite a need for financing reforms that better incentivize addressing patient whole health and wellness, the lack of clear standardization of social determinants of health screening tools, interoperable data collection systems, lack of robust health-related social services expenditure data, and financing uncertainties and insecurities present significant challenges for value-based payment arrangements, according to this analysis.
AcademyHealth and the National Pharmaceutical Council (NPC) consider the drivers of health spending in the U.S. through salons focused on challenging questions. Today’s post takes a closer look at how the macro health economy may evolve post-pandemic.
The annual Reinhardt Lecture honors a national leader who reflects the high standards of Professor Uwe Reinhardt. The 2021 lecturer was Dr. Sherry Glied, who honored Dr. Reinhardt’s trailblazing focus on price, rather than quantity, with a discussion of the role of price as a market signal. The following plain language summary offers highlights from the transcribed remarks, as delivered at the virtual 2021 Annual Research Meeting and published in the journal Health Services Research.
As the Centers for Medicare and Medicaid Services (CMS) moves to strengthen its price transparency efforts, a panel of experts recently discussed what advancements are necessary to provide consumers with accurate, useful information to make informed decisions about the cost and quality of care.
Understanding the economic impact of health interventions is critical for developing effective programs that can be replicated in different settings. At the 13th Annual Conference on the Science of Dissemination and Implementation in Health, experts shared their top tips about evaluating the economics of a new or existing initiative.
This month’s “Read on Washington,” available only to AcademyHealth members, includes updates on appropriations bills, negotiations to expand Medicare, an executive order to combat drug and medical prices, VA mandates for COVID-19 vaccines, and more.
AcademyHealth Director Lauren Gerlach and Mona Shah of the Robert Wood Johnson Foundation discuss the importance of rigorous evaluation of Section 1115 Medicaid demonstration waivers.
In a recent webinar in collaboration with the National Pharmaceutical Council, experts discussed how to evaluate SDOH programs and interventions from a cost perspective. Speakers emphasized the incomplete state of current knowledge and the need to improve studies and data infrastructure to determine their value.
This webinar was part of series which seeks to promote serious evidence-based discussions related to costs, value, and allocation of health care spending.
Date & Time May 4, 2021 | 3:00 p.m. - 4:00 p.m. ET
Location Online
It is medically, ethically, and legally imperative that measures aimed at protecting vulnerable patients are not undermined by the burdensomeness of exemption procedures, or by physicians’ political or personal views.
